PARTI Overview We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders. Our lead product ...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-034880 | EDGAR | 88K words |
| 2025-03-20 | 2024-12-31 | 0001558370-25-003341 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003949 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001558370-23-004401 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001558370-22-004672 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001104659-26-092362 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107402 | EDGAR | 24K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010771 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001558370-25-006612 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015436 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011464 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-006911 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017321 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013741 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008117 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017604 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012749 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001104659-26-092037 | EDGAR | — |
| 2026-03-26 | 0001104659-26-034876 | EDGAR | 3K words |
| 2026-03-02 | 0001104659-26-021904 | EDGAR | — |
| 2026-01-27 | 0001104659-26-006813 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122555 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107390 | EDGAR | — |
| 2025-09-15 | 0001104659-25-089737 | EDGAR | — |
| 2025-08-28 | 0001104659-25-084845 | EDGAR | — |
| 2025-08-26 | 0001104659-25-083059 | EDGAR | — |
| 2025-08-07 | 0001104659-25-075268 | EDGAR | — |
105 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001455365 |
| Ticker | CGTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cogrx.com |
| Listed | 2021-10-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CGTX (~200 tokens, structured JSON with cryptographic provenance)